162 related articles for article (PubMed ID: 4077563)
1. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K
Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
[TBL] [Abstract][Full Text] [Related]
2. Desferrioxamine induced urinary iron excretion in thalassemia.
Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
[TBL] [Abstract][Full Text] [Related]
3. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
Wali YA; Taqi A; Deghaidi A
Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
[TBL] [Abstract][Full Text] [Related]
4. Intensification of chelating-therapy in patients with thalassemia major.
Laws HJ; Göbel U; Christaras A; Janssen G
Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
[TBL] [Abstract][Full Text] [Related]
5. [Chelating therapy in beta-thalassemia].
Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
Flynn DM; Hoffbrand AV; Politis D
Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
[No Abstract] [Full Text] [Related]
7. [Arrhythmia in thalassemia major: evaluation of iron chelating therapy by dynamic ECG].
Cavallaro L; Meo A; Busà G; Coglitore A; Sergi G; Satullo G; Donato A; Calabrò MP; Miceli M
Minerva Cardioangiol; 1993; 41(7-8):297-301. PubMed ID: 8233011
[TBL] [Abstract][Full Text] [Related]
8. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Wolfe L; Olivieri N; Sallan D; Colan S; Rose V; Propper R; Freedman MH; Nathan DG
N Engl J Med; 1985 Jun; 312(25):1600-3. PubMed ID: 4000198
[TBL] [Abstract][Full Text] [Related]
9. Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
De Virgiliis S; Cossu P; Toccafondi C; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Loi A; Bertolino F; Cao A
Am J Pediatr Hematol Oncol; 1983; 5(1):73-7. PubMed ID: 6859457
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of iron overload in thalassemia].
Piga A; Davico S; Magliano M; Luzzatto L; Sandri A; Gabutti V
Pediatr Med Chir; 1986; 8(1):9-13. PubMed ID: 3725619
[TBL] [Abstract][Full Text] [Related]
11. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
[TBL] [Abstract][Full Text] [Related]
12. The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B.
Bayraktar Y; Saglam F; Temizer A; Uzunalimodlu B; van Thiel DH
Hepatogastroenterology; 1998; 45(24):2322-7. PubMed ID: 9951916
[TBL] [Abstract][Full Text] [Related]
13. Iron studies in infants born to an iron overloaded mother with beta-thalassemia major: possible effects of maternal desferrioxamine therapy.
Pearson HA
J Pediatr Hematol Oncol; 2007 Mar; 29(3):160-2. PubMed ID: 17356394
[TBL] [Abstract][Full Text] [Related]
14. Self-reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias.
Lee WS; Toh TH; Chai PF; Soo TL
J Paediatr Child Health; 2011 Aug; 47(8):535-40. PubMed ID: 21392144
[TBL] [Abstract][Full Text] [Related]
15. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
Ambruso DR; Mahony BS; Githens JH; Rhoades ED
Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
[TBL] [Abstract][Full Text] [Related]
16. Iron chelation in thalassemia: mechanism of desferrioxamine action.
Hershko C; Rachmilewitz EA
Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
[TBL] [Abstract][Full Text] [Related]
17. [Thalassemia major: chelating therapy with deferoxamine].
Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
[No Abstract] [Full Text] [Related]
18. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion.
Yarali N; Fişgin T; Duru F; Kara A; Ecin N; Fitoz S; Erden I
J Pediatr Hematol Oncol; 2006 Jan; 28(1):11-6. PubMed ID: 16394886
[TBL] [Abstract][Full Text] [Related]
19. Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results.
Kovarik J; Irschik H; Graf H; Woloszczuk W; Meisinger V; Linkesch W; Stummvoll HK
Contrib Nephrol; 1985; 49():44-55. PubMed ID: 3830570
[TBL] [Abstract][Full Text] [Related]
20. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
